MedPath

A clinical Trial in patients with inflammatory ocular conditions where bacterial infection or a risk of bacterial ocular infection exists. Clinical trial is to study efficacy, safety and tolerability of Moxifloxacin plus Bromfenac eye drops in comparison to Gatifloxacin plus Dexamethasone eye drops.

Phase 3
Completed
Conditions
Ocular pain,
Registration Number
CTRI/2010/091/000280
Lead Sponsor
Ajanta Pharma Ltd
Brief Summary

This study is a Comparative, Randomized, Double blind, Multicentric, Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Moxifloxacin 0.5% w/v + Bromfenac 0.09% w/v eye drops Vs. Gatifloxacin 0.3% + Dexamethasone 0.1% eye drops in 100 patients with inflammatory ocular conditions where bacterial infection or a risk of bacterial ocular infection exists. xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /

 The primary outcome measures will be assessed by Slit Lamp Biomicroscopy at day 1, Day 3, Day 5 and Day 7. The secondary outcome measures will be assessed by Conjunctival hyperaemia, corneal and lid oedema, Ocular Infection, pain, photophobia and tearing at day 1, Day 3, Day 5 and Day 7.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Patients who have undergone cataract surgery, vitreous surgery or both (including patients who have undergone IOL insertion surgery at the same time) 2.
  • Written informed consent to participate to the trial.
Exclusion Criteria
  • Patients < 18 & > 60 years.2. Patients who took systemic administration of corticosteroids or immunosuppressive agents, or used ophthalmic ointments of corticosteroids within 1 week before instillation of the investigational drugs; 3.
  • Patients who underwent local injection of corticosteroids in the eyes before instillation of the investigational drugs; (patients who used aqueous preparations within 1 week or patient who used depot preparations within 2 weeks were excluded) 4.
  • Patients who took systemic administration of non-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 3 days before instillation of the investigational drugs; 5.
  • Patients who instilled of corticosteroids, no-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 24 hours before the pre-instillation observation (a day after surgery); 6.
  • Patients who underwent preoperative and/or postoperative intravitreous injection of corticosteroids; 7.
  • Patients who underwent sub-conjunctival injection 8.
  • Patients who have intraocular hemorrhage with a degree that may affect the postoperative evaluations; 9.
  • Patients who underwent gas tamponade at the surgery; 10.
  • Patients with endogenous uveitis; 11.
  • Patients having corneal epithelial detachment or corneal ulcer in the target eye; 12.
  • Patients who have allergy to corticosteroid drugs; 13.
  • Patients who are required to wear contact lens during the study period; 14.
  • Patients who are scheduled to undergo surgery of the opposite eye during the study period; 15.
  • Patients who are pregnant or may be pregnant or lactating; 16.
  • Patients who have participated in other clinical studies within 3 months.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Slit Lamp BiomicroscopyDay 1,Day 3, Day 5 and Day 7.
Secondary Outcome Measures
NameTimeMethod
Conjunctival hyperaemia, corneal and lid oedema, Ocular Infection, pain, photophobia and tearingDay 1,Day 3, Day 5 and Day 7.

Trial Locations

Locations (3)

Dr. Sharad Mistrys Clinic

🇮🇳

Thane, MAHARASHTRA, India

Murlidhar Nursing and Maternity Home

🇮🇳

Thane, MAHARASHTRA, India

Nakshatra Netralaya

🇮🇳

Latur, MAHARASHTRA, India

Dr. Sharad Mistrys Clinic
🇮🇳Thane, MAHARASHTRA, India
Dr Sharad Mistry
Principal investigator
09821711054
esmile1614@yahoo.co.in

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.